Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of CX-2009 in advanced solid tumors
NL-OMON48575Phase 2Completed
- Sponsor
- CytomX Therapeutics, Inc.
- Start
- Oct 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of praluzatamab ravtansine and pacmilimab in Nonhematologic neoplasms, breast cancer, prostate cancer (PCa) and 5 more (9 arms), sponsored by CytomX Therapeutics, Inc. Primary endpoints: Safety profile, Maximum tolerated dose / recommended Phase 2 dose and 7 more. Started Oct 2018; status: completed.
02
Drugs
praluzatamab ravtansinepacmilimab
03
Conditions
Nonhematologic neoplasmsbreast cancerprostate cancer (PCa)non-small cell lung cancer (NSCLC)epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NL-OMON48575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48575.